Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats
Open Access
- 31 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e77969
- https://doi.org/10.1371/journal.pone.0077969
Abstract
Berberine (BBR) has been confirmed to have multiple bioactivities in clinic, such as cholesterol-lowering, anti-diabetes, cardiovascular protection and anti- inflammation. However, BBR’s plasma level is very low; it cannot explain its pharmacological effects in patients. We consider that the in vivo distribution of BBR as well as of its bioactive metabolites might provide part of the explanation for this question. In this study, liquid chromatography coupled to ion trap time-of-flight mass spectrometry (LC/MSn-IT-TOF) as well as liquid chromatography that coupled with tandem mass spectrometry (LC-MS/MS) was used for the study of tissue distribution and pharmacokinetics of BBR in rats after oral administration (200 mg/kg). The results indicated that BBR was quickly distributed in the liver, kidneys, muscle, lungs, brain, heart, pancreas and fat in a descending order of its amount. The pharmacokinetic profile indicated that BBR’s level in most of studied tissues was higher (or much higher) than that in plasma 4 h after administration. BBR remained relatively stable in the tissues like liver, heart, brain, muscle, pancreas etc. Organ distribution of BBR’s metabolites was also investigated paralleled with that of BBR. Thalifendine (M1), berberrubine (M2) and jatrorrhizine (M4), which the metabolites with moderate bioactivity, were easily detected in organs like the liver and kidney. For instance, M1, M2 and M4 were the major metabolites in the liver, among which the percentage of M2 was up to 65.1%; the level of AUC (0-t) (area under the concentration-time curve) for BBR or the metabolites in the liver was 10-fold or 30-fold higher than that in plasma, respectively. In summary, the organ concentration of BBR (as well as its bioactive metabolites) was higher than its concentration in the blood after oral administration. It might explain BBR’s pharmacological effects on human diseases in clinic.Keywords
This publication has 39 references indexed in Scilit:
- Berberine and Itraconazole Are not Synergistic in Vitro against Aspergillus fumigatus Isolated from Clinical PatientsMolecules, 2011
- Bioavailability Study of Berberine and the Enhancing Effects of TPGS on Intestinal Absorption in RatsAAPS PharmSciTech, 2011
- Bioactivities of berberine metabolites after transformation through CYP450 isoenzymesJournal of Translational Medicine, 2011
- Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cellsMolecular Cancer, 2011
- Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic GluconeogenesisPLOS ONE, 2011
- Determination of berberine in human plasma by liquid chromatography–electrospray ionization–mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2007
- Rapid separation and identification of phenolic and diterpenoid constituents from Radix Salvia miltiorrhizae by high‐performance liquid chromatography diode‐array detection, electrospray ionization time‐of‐flight mass spectrometry and electrospray ionization quadrupole ion trap mass spectrometryRapid Communications in Mass Spectrometry, 2007
- Simultaneous determination of berberine and palmatine in rat plasma by HPLC–ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the pharmacokinetic application of the methodJournal of Pharmaceutical and Biomedical Analysis, 2006
- Neutralization of Transthyretin Reverses the Neuroprotective Effects of Secreted Amyloid Precursor Protein (APP) in APPSwMice Resulting in Tau Phosphorylation and Loss of Hippocampal Neurons: Support for the Amyloid HypothesisJournal of Neuroscience, 2004
- Effects of Berberine on Delayed Afterdepolarizations in Ventricular Muscles In Vitro and In VivoJournal of Cardiovascular Pharmacology, 1994